Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition
Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis
Sex
Male or Female
Age
2 - 17 years
Healthy participants
No

Eligibility criteria

Study overview

This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study.

Xeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea.

This study is seeking patients who:

  • Are 2 to less than 18 years of age;
  • Are given Xeljanz for the treatment of JIA.


The study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.

View locations for this study

Find the closest location, your results will be shown below
Find the closest location
    Miles
    0500

    Nearest Locations found

    1 site found

    Pfizer

    Seoul, South Korea
    recruiting status
    Recruiting
    Site Info
    • Recruitment Status
    • Site details
    • Study Contact
    • Clinical Trials ID

    Study Locations

    View locations for this studyFind the closest location, your results will be shown belowFind the closest location